Financial Position - Cash position as of June 30, 2025, was $18.0 million, expected to fund operations into mid-2026[7] - Total assets as of June 30, 2025, were $19.1 million, a decrease from $19.8 million at the end of 2024[16] Research and Development - Research and development expenses for Q2 2025 were $4.1 million, a slight decrease from $4.2 million in Q2 2024[7] - Enrollment ongoing in the Phase 2 KOURAGE trial of Auxora™ for acute kidney injury (AKI) with respiratory failure, targeting 150 patients with data expected in early 2026[4] - Initial meeting with the FDA regarding Auxora in acute pancreatitis (AP) was productive, with alignment on a pivotal trial anticipated around the end of 2025[3] - The company presented a symposium on Auxora for AKI at the 43rd Vicenza Course in June 2025, highlighting its clinical significance[8] - The manuscript published in the American Journal of Nephrology supports Auxora's potential as a treatment for AKI[4] Financial Performance - Net loss for Q2 2025 was $6.0 million, or $0.40 per share, compared to a net loss of $4.0 million, or $0.36 per share, in Q2 2024[10] - Total operating expenses for Q2 2025 were $6.6 million, compared to $6.5 million in Q2 2024[18] - Other income for Q2 2025 was $0.7 million, down from $2.6 million in Q2 2024, primarily due to a decrease in fair value adjustments[10]
Grayscale Investments(GRAY) - 2025 Q2 - Quarterly Results